Abstract: An eyeball detection unit of the present disclosure includes an irradiator that projects substantially parallel illumination light toward a cornea of an eyeball, a detector that detects light intensity of reflected light from the cornea, and a detection controller that identifies a centroid offset in an angular direction of the light intensity of the reflected light from the cornea with respect to a reference optical axis on the basis of a detected value by the detector, and thereafter calculates a positional offset of a cornea position with respect to the reference optical axis.

Abstract: An eyeball detection unit of the present disclosure includes an irradiator that projects substantially parallel illumination light toward a cornea of an eyeball, a detector that detects light intensity of reflected light from the cornea, and a detection controller that identifies a centroid offset in an angular direction of the light intensity of the reflected light from the cornea with respect to a reference optical axis on the basis of a detected value by the detector, and thereafter calculates a positional offset of a cornea position with respect to the reference optical axis.

Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.

Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.

Abstract: An image output apparatus includes a light emitting unit, a power supplying unit, and a control unit. The light emitting unit is configured to emit a laser beam. The power supplying unit is configured to supply power to the light emitting unit at a predetermined voltage. The control unit is configured to control the power supplying unit to supply the power to the light emitting unit in a predetermined period at the voltage associated with a peak light emission amount of the light emitting unit in image data for the predetermined period.

Abstract: An image output apparatus includes a light emitting unit, a power supplying unit, and a control unit. The light emitting unit is configured to emit a laser beam. The power supplying unit is configured to supply power to the light emitting unit at a predetermined voltage. The control unit is configured to control the power supplying unit to supply the power to the light emitting unit in a predetermined period at the voltage associated with a peak light emission amount of the light emitting unit in image data for the predetermined period.

Abstract: The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker.

Abstract: Disclosed are a novel method of screening for insulin secretion-potentiating agents as well as means for performing such screening. The means include a DNA encoding fluorescent-labeled Epac2 comprising two different DNAs encoding two different fluorescent proteins which emit fluorescent light with wavelength differing from each other and a DNA encoding Epac2 which are fused together in-frame, and the cells transformed with the DNA. Also disclosed is a method of screening insulin secretion-potentiating agents comprising bringing a candidate compound into contact with cells transformed with the said DNA, and detecting whether the compound binds to Epac2.

Abstract: The present invention makes it possible to set an operating condition enabling the best recording characteristic to be obtained for any kind of recording media, even in the case where the recording medium is combined with any kind of drive devices. According to the present invention, even in the case where a unknown and new kind of recording medium is loaded into the drive device, a piece of first operating condition information for an optical system suitable for a combination of the drive device and the new kind of recording media is read from a specific read only area provided for the recording medium, and an operating condition enabling the best operating characteristic to be obtained is set by using the first operating condition information, as a result of which even in the case where any kind of recording medium and any kind of drive device are combined, the operating condition for enabling the best recording characteristic to be obtained for the recording medium, can be set in the drive device.

Abstract: Disclosed is a method for producing insulin secreting cells to be used in cell transplantation therapy of diabetes, by induction from pancreatic acinar cells in culture vessels. The method comprises culturing pancreatic acinar cells isolated from a mammal in a medium containing a growth factor, preferably epidermal growth factor, fibroblast growth factor and/or hepatocyte growth factor, to induce insulin secreting cells.

Abstract: The present invention makes it possible to set an operating condition enabling the best recording characteristic to be obtained for any kind of recording media, even in the case where the recording medium is combined with any kind of drive devices. According to the present invention, even in the case where a unknown and new kind of recording medium is loaded into the drive device, a piece of first operating condition information for an optical system suitable for a combination of the drive device and the new kind of recording media is read from a specific read only area provided for the recording medium, and an operating condition enabling the best operating characteristic to be obtained is set by using the first operating condition information, as a result of which even in the case where any kind of recording medium and any kind of drive device are combined, the operating condition for enabling the best recording characteristic to be obtained for the recording medium, can be set in the drive device.

Abstract: Disclosed are a mouse homozygous or heterozygous for the defect of the Noc2 gene, and a tissue and a cell of the mouse. The Noc2 knockout mice, which exhibit stress-related insulin hyposecretion and accumulation of secretory granules of increased size and irregular shape in exocrine cells, provide a test system used in the development of therapeutic drugs for related disorders.

Abstract: Mice homozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are disclosed. The mice causes a high incidence of sudden death associated with arrhythmia (atrioventricular block) caused by spontaneous cardiac ischemia, a condition similar to Prinzmetal angina (variant angina) in human, representing an animal model of Prinzmetal angina. Mice heterozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are also disclosed, which are used as parent mice for reproduction of the homozygous mice.

Abstract: The present invention discloses DNAs comprising nucleotide sequences set forth as SEQ ID NO:1 or NO:3 encoding Na+-driven Cl?/HCO3? exchanger, proteins comprising amino acid sequences set forth as SEQ ID NO:2 or NO:4, and their homologous proteins comprising an amino acid sequence having deletion, substitution, addition or insertion amino acids, which proteins, when expressed in a cell, functions as Na+-driven Cl?/HCO3? exchanger, and cells in which the proteins exogenously expressed.

Abstract: Disclosed are a mouse homozygous or heterozygous for the defect of the Noc2 gene, and a tissue and a cell of the mouse. The Noc2 knockout mice, which exhibit stress-related insulin hyposecretion and accumulation of secretory granules of increased size and irregular shape in exocrine cells, provide a test system used in the development of therapeutic drugs for related disorders.

Abstract: Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or added relative to the amino acid sequence set forth under SEQ ID NO:1 in the Sequence Listing and which has a property to interact with GDP/GTP exchange factor II.

Abstract: This invention makes it possible to increase a recording transfer rate while keeping recording characteristics with simple control, regardless of change of linear velocity. According to this invention, when data is written on or erased from an optical disk 100, a write pulse on a temporal axis is corrected by using a recording strategy suitable for a linear velocity, without adjusting write power set in consideration of the recording characteristics of the optical disk 100. Therefore, this invention can increase a recording transfer rate with keeping the same recording characteristics, with simple control of only correction of the write pulse on the temporal axis, regardless of change of the write pulse.

Abstract: To realize a disk drive device capable of setting optimum recording power by obtaining amplitude information of a reproduced signal even when low recording power is used. A disk drive device for recording and reproducing data on/from an optical disk is provided with: a Viterbi decoding means for performing Viterbi decoding on a reproduced signal reproduced from an optical disk to decode data and creating status data representing a status transition in the Viterbi decoding; and a quality index creation means for calculating a differential value between an amplitude reference value corresponding to the status transition recognized from the status data and a reproduced signal value created by digitizing the reproduced signal and creating a quality index value representing quality of the reproduced signal based on the differential value.

Abstract: Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or added relative to the amino acid: sequence set forth under SEQ ID NO:1 in the Sequence Listing and which has a property to interact with GDP/GTP exchange factor II.

Abstract: Mice homozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are disclosed. The mice causes a high incidence of sudden death associated with arrhythmia (atrioventricular block) caused by spontaneous cardiac ischemia, a condition similar to Prinzmetal angina (variant angina) in human, representing an animal model of Prinzmetal angina. Mice heterozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are also disclosed, which are used as parent mice for reproduction of the homozygous mice.